M2537
Mevastatin
≥98% (HPLC), 3-hydroxy 3-methyl glutaryl coenzyme(A) reductase (HMG-CoA reductase) inhibitor, powder or crystals
동의어(들):
Compactin, ML-236B
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C23H34O5
CAS 번호:
Molecular Weight:
390.51
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Beilstein/REAXYS Number:
1269441
제품 이름
Mevastatin, ≥98% (HPLC), powder or crystals
Quality Level
assay
≥98% (HPLC)
form
powder or crystals
color
white to light yellow
mp
151 °C
solubility
ethanol: 25-26 mg/mL, clear, colorless
antibiotic activity spectrum
neoplastics
mode of action
enzyme | inhibits
originator
Daiichi-Sankyo
storage temp.
2-8°C
SMILES string
[H][C@]12[C@H](CCC=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)[C@@H](C)CC
InChI
1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
InChI key
AJLFOPYRIVGYMJ-INTXDZFKSA-N
Gene Information
human ... HMGCL(3155), HMGCR(3156)
rat ... Hmgcr(25675)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
General description
Chemical structure: statin
Mevastatin is a polyketide that belongs to the class of statins. It contains a hydroxy-hexahydronaphthalene ring.
Application
Mevastatin has been used:
- to analyze its effects on chronic lymphocytic leukemia (CLL) cells by cytotoxic assay
- as a prenylation inhibitor to analyze its effects on human embryonic kidney (HEK) cells transfected with K-Ras
- as a statin agent to study its anti-cancer effect on human breast cancer cells and glioblastoma in vitro
Biochem/physiol Actions
Mevastatin is a selective inhibitor of 3-hydroxy 3-methyl glutaryl coenzyme(A) reductase (HMG-CoA reductase), a major enzyme involved in cholesterol synthesis. It acts as a cholesterol-lowering agent. Mevastatin is obtained from various species of fungi. It acts as an antiresorptive agent and has therapeutic effects to treat osteoporosis. Mevastatin inhibits bone resorption by triggering osteoclast apoptosis. It is also involved in the inhibition of prenylation of proteins such as Ras. Mevastatin increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels by blocking the geranylgeranylation of transcription factor Rho.
Features and Benefits
This compound was developed by Daiichi-Sankyo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
C M Shipman et al.
Cancer research, 58(23), 5294-5297 (1998-12-16)
It has recently been suggested that bisphosphonates may have direct antitumor effects in vivo, in addition to their therapeutic antiresorptive properties. Bisphosphonates can inhibit proliferation and cause apoptosis in human myeloma cells in vitro. In macrophages, bisphosphonate-induced apoptosis was recently
F P Coxon et al.
Molecular pharmacology, 54(4), 631-638 (1998-10-10)
The exact mechanisms of action of antiresorptive bisphosphonate drugs remain unclear, although they may inhibit bone resorption by mechanisms that can lead to osteoclast apoptosis. These drugs also cause apoptosis in J774 macrophages, probably as a consequence of inhibition of
J T Woo et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 15(4), 650-662 (2000-04-26)
Compactin (mevastatin), which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and thus biosynthesis of cholesterol and the prenylation of proteins, inhibits osteoclastic bone resorption. Although it has been suggested that compactin inhibits bone resorption by inducing apoptosis of osteoclasts, the pathway by
U Laufs et al.
The Journal of biological chemistry, 273(37), 24266-24271 (1998-09-03)
The mechanism by which 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors increase endothelial nitric oxide synthase (eNOS) expression is unknown. To determine whether changes in isoprenoid synthesis affects eNOS expression, human endothelial cells were treated with the HMG-CoA reductase inhibitor, mevastatin (1-10 microM)
S P Luckman et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 13(4), 581-589 (1998-04-29)
Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates have not been identified, these compounds inhibit bone resorption by mechanisms that can lead to osteoclast
문서
Discover Bioactive Small Molecules for Lipid Signaling Research
Cholesterol synthesis regulation by dietary levels, LDL receptors control lipid-rich LDL particle transport in cells.
지질 신호전달 연구를 위한 생체 활성 저분자
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.